What We're Reading: Page 129
Industry reads hand-picked by our editors
Aug 03, 2022
-
Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars
-
STAT
AbbVie’s ‘patent thickets’ for Humira don’t thwart competition, court rules
-
The Wall Street Journal
Moderna Profit Falls Amid Charges for Unused Covid-19 Vaccines
-
FierceBiotech
Genentech, AC Immune reveal more about crenezumab failure
Aug 02, 2022
-
The Seattle Times
Clay Siegall built Seattle biotech firm Seagen into a $1.6B giant. Then the cops came calling
-
ProPublica
After Receiving Millions in Drug Company Payments, Pain Doctor Settles Federal Kickback Allegations
-
The Washington Post
Biden names FEMA’s Robert Fenton as monkeypox response coordinator
-
STAT
Cities are lobbying to host ARPA-H. Experts don’t understand why
Aug 01, 2022
-
The Washington Post
‘Not enough shots’: U.S. faces ‘vaccine cliff’ on monkeypox
-
The Wall Street Journal
Amgen Fights IRS Over $10.7 Billion Tax Bill
-
NPR
Alzheimer’s researchers are looking beyond plaques and tangles for new treatments
-
Fierce Biotech
FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should ‘move into a new phase’
Jul 29, 2022
-
The New York Times
Biden Administration Plans to Offer Updated Booster Shots in September
-
BioCentury
Califf warns of dangers of user fee brinkmanship
-
The Boston Globe
This billionaire has quietly driven Boston’s biotech industry for decades
Jul 28, 2022
Jul 27, 2022
-
Business Insider
Kids with 'bubble boy' disease are dying — even though drug companies have found a cure
-
The Washington Post
Biden administration estimates U.S. may need nearly $7 billion for monkeypox
-
Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement
-
Reuters
Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say
Previous
